Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ADHELASKIN (Tactinnov° - Ecole centrale de Lyon).
- Who it may be relevant to
- Registry conditions: D013493. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, which clinically manifests as thickening, hardening, and loss of elasticity of the skin. Patients are typically classified as having diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) depending on the extent of skin fibrosis. The standard assessment of cutaneous sclerosis is based on the modified Rodnan skin score (mRSS), which consists of clinical palpation of 17 areas of the body, scored from 0 (normal) to 3 (severe sclerosis) for each area, with a total of 51 points. However, the mRSS has several limitations, including high inter- and intra-observer variability, particularly depending on the clinician's experience, subjectivity of palpation with difficulties in quantifying subtle changes in firmness or elasticity, and limited sensitivity to small changes or in areas that are not severely affected. The assessment of skin fibrosis therefore faces a lack of objective, quantitative tools that are easy to use in routine clinical practice. Certain alternatives have been evaluated (durometer, ultrasound, elastography, etc.), but none has yet been fully adopted or validated for measuring firmness, elasticity, and adhesion at different depths of the skin with good accuracy and reproducibility. ADHELASKIN° technology (by Tactinnov, LTDS / École Centrale de Lyon) enables objective, highly sensitive measurement of rigidity, firmness and elasticity using an indentation method with a ruby ball sensor. The objective of our study is to assess whether the ADHELASKIN device can differentiate between the biomechanical properties of healthy patients and those of patients with SSc.
Interventions
- Device ADHELASKIN (Tactinnov° - Ecole centrale de Lyon)
Evaluation of stiffness, elastic modulus and pile-up height for ScS patients and controls by ADHELASKIN device
Primary outcome measures
- Objectively compare skin stiffness in patients with systemic sclerosis versus healthy patients [Time frame: Day 1]
Secondary outcome measures (7)
- Compare skin stiffness in different areas in patients with systemic sclerosis vs. healthy patients [Time frame: Day 1]
- Objectively compare skin elasticity in patients with systemic sclerosis vs. healthy patients. [Time frame: Day 1]
- Objectively compare skin firmness in patients with systemic sclerosis vs. healthy patients. [Time frame: Day 1]
- Evaluate an association between the stiffness, elasticity, and firmness measurements obtained using the ADHELASKIN device and the mRSS score. [Time frame: Day 1]
- Estimate the patient experience of skin assessment using ADHELASKIN [Time frame: Day 1]
- Estimate inter-investigator variability in stiffness measurement using ADHELASKIN [Time frame: Day 1]
- Compare the duration of skin stiffness measurement examinations of 17 body regions by mRSS score and using ADHELASKIN [Time frame: Day 1]
Eligibility criteria
Inclusion criteria
- Patients affiliated with or eligible for social security
- Patients who have received informed consent about the study and have co-signed, with the investigator, a consent form to participate in the study
- For case patients: Patients with SSc according to the 2013 ACR/EULAR criteria
- For healthy patients: Patients without significant skin lesions who are outpatients or inpatients at a department of the Saint-Etienne University Hospital
- For healthy volunteers: Volunteers without significant skin lesions who work at the Saint-Etienne University Hospital and whose participation in the study does not require any special travel
Exclusion criteria
- Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than research;
- Adults subject to legal protection measures (guardianship-curatorship) or unable to express their consent
- Inflammatory or scarring dermatoses in different individuals
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- CHU de Saint-Etienne — Saint-Priest-en-Jarez
Identifiers
NCT: NCT07543679 · 26CH041 · ANSM